ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Should You Buy?

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) gapped up prior to trading on Tuesday . The stock had previously closed at $6.66, but opened at $7.15. ImmunityBio shares last traded at $7.2730, with a volume of 4,053,744 shares traded.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced $100 million of financing transactions, including $75 million of non‑dilutive financing under its Royalty Interest Purchase Agreement (RIPA), which strengthens the balance sheet to support global expansion and pipeline work. Article Link
• Positive Sentiment: Recent operational momentum: the company posted a notably strong quarter and earlier headlines reported a rally after raising capital for expansion — positive signals for revenue runway and commercialization. Article Link
• Neutral Sentiment: High short‑term volatility: analysts and commentators (including Jim Cramer and sector writeups) are urging cautious, speculation‑sized positions — useful for timing but not a driver of fundamentals. Article Link
• Negative Sentiment: FDA warning letter: the FDA determined promotional communications about Anktiva contained misleading efficacy claims, which raises regulatory risk for the product’s commercial messaging and could prompt further scrutiny. Article Link
• Negative Sentiment: Multiple securities class actions filed or solicited: several law firms (Hagens Berman, Rosen, Levi & Korsinsky, Kahn Swick & Foti, others) have filed or are soliciting plaintiffs alleging the company misled investors between Jan. 19 and Mar. 24, 2026 — litigation risk and potential damages could weigh on the stock. Article Link
• Negative Sentiment: Market reaction: press reports note a sharp intraday decline and an estimated ~$2 billion market‑cap reduction after the FDA notice — amplified selling and litigation headlines are accelerating price pressure. Article Link

Analyst Upgrades and Downgrades

IBRX has been the subject of a number of analyst reports. Jefferies Financial Group raised their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. BTIG Research initiated coverage on shares of ImmunityBio in a research report on Thursday, March 12th. They set a “buy” rating and a $13.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research note on Monday, March 23rd. HC Wainwright raised their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

ImmunityBio Price Performance

The firm’s 50 day moving average is $7.73 and its two-hundred day moving average is $4.33. The firm has a market capitalization of $7.34 billion, a P/E ratio of -18.79 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. Analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Transactions at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the sale, the director owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. This trade represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 501,967 shares of company stock worth $4,466,412. 69.48% of the stock is owned by insiders.

Institutional Trading of ImmunityBio

A number of hedge funds have recently made changes to their positions in IBRX. Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of ImmunityBio during the 4th quarter worth approximately $59,000. Invesco Ltd. raised its stake in ImmunityBio by 14.6% in the 4th quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock valued at $362,000 after acquiring an additional 23,353 shares during the period. Corient Private Wealth LLC raised its stake in ImmunityBio by 69.7% in the 4th quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after acquiring an additional 136,858 shares during the period. EP Wealth Advisors LLC acquired a new stake in ImmunityBio during the 4th quarter valued at $35,000. Finally, Empowered Funds LLC acquired a new stake in ImmunityBio during the 4th quarter valued at $28,000. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.